Published in Oncology on June 30, 1994
Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res (2012) 0.77
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol (1995) 1.77
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol (1989) 1.69
Autoantibodies in neoplasia. An unresolved enigma. Cancer (1990) 1.45
Diffuse lung uptake of Ga-67 after treatment of lymphoma: is it of clinical importance? Radiology (1996) 1.41
Gallium-67 scintigraphy in lymphoma with bone involvement. J Nucl Med (1995) 1.39
Non-Hodgkin's lymphoma presenting with spinal epidural involvement. Cancer (1986) 1.33
Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients. Am J Med (1997) 1.32
Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod (1996) 1.27
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
Low PSA metastatic androgen- independent prostate cancer. Eur Urol (2000) 1.20
Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service. Support Care Cancer (2000) 1.12
Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases. Ann Oncol (1995) 1.09
Malignant lymphoma in first-degree blood relatives. Cancer (1982) 1.09
PAGET'S DISEASE AND MALE BREAST CANCER. Isr Med Assoc J (2015) 1.08
Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer (1990) 1.08
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer (1991) 1.02
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer (2001) 1.01
Echocardiography in nonbacterial thrombotic endocarditis: from autopsy to clinical entity. J Am Soc Echocardiogr (2000) 1.00
Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. Int J Radiat Oncol Biol Phys (1999) 0.99
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol (1989) 0.98
Second neoplasms in patients with Merkel cell carcinoma. Cancer (2001) 0.98
Primary Hodgkin's disease of the bone. Med Pediatr Oncol (1995) 0.97
DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res (1988) 0.97
The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer (1997) 0.96
Chemotherapy-induced spontaneous pneumothorax in a patient with bulky mediastinal lymphoma: a rare oncologic emergency. Oncology (1997) 0.94
Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer (1990) 0.94
Primary lymphoma of bone--a retrospective study. Experience at the Northern Israel Oncology Center (1979-2000). Oncology (2003) 0.93
The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study. Cancer (2000) 0.93
5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage. Oncology (1989) 0.92
Postirradiation soft tissue sarcoma occurring in breast cancer patients: report of seven cases and results of combination chemotherapy. J Surg Oncol (1985) 0.92
Topical superoxide dismutase reduces post-irradiation breast cancer fibrosis. J Cell Mol Med (2004) 0.92
Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci (1989) 0.92
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer (2004) 0.91
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol (2009) 0.91
Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (1994) 0.90
Early development of vaginal shortening during radiation therapy for endometrial or cervical cancer. Int J Gynecol Cancer (2001) 0.90
Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst (1991) 0.90
Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst (1979) 0.89
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol (1994) 0.88
Benign proliferative lesions mimicking recurrence of Hodgkin's disease. Med Pediatr Oncol (1997) 0.88
Properties of a putative muscarinic cholinergic receptor from Drosophila melanogaster. J Neurochem (1979) 0.88
Haptoglobin-related protein as a serum marker in malignant lymphoma. Pathol Oncol Res (1998) 0.88
In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochem Pharmacol (1987) 0.88
Correlation of erythrocyte and plasma levels of zinc, copper, and iron with evidence of metastatic spread in cancer patients. Cancer (1985) 0.87
Topical Biafine and Lipiderm for the prevention of radiation dermatitis: a randomized prospective trial. Oncol Rep (2001) 0.87
Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. Am J Clin Oncol (1998) 0.87
Colorectal cancer in young patients in Israel: a distinct clinicopathological entity? World J Surg (2010) 0.86
Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun (1986) 0.86
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (1995) 0.86
Prevention of gonadal damage during cytotoxic therapy. Ann Med (1997) 0.85
Isolated pericardial metastasis of parotid tumor origin. Head Neck Surg (1982) 0.85
Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res (1988) 0.85
Pericardial effusion as first evidence of malignancy in bronchogenic carcinoma. J Surg Oncol (1982) 0.84
Cancer and thrombosis revisited. Blood Rev (2001) 0.83
A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma. Cancer Biother Radiopharm (1998) 0.83
Sex hormone binding globulin (SHBG) in breast cancer: a correlation with obesity but not with estrogen receptor status. Eur J Cancer Clin Oncol (1984) 0.83
Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer (2002) 0.83
Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology (1999) 0.83
Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology (2000) 0.83
Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep (1987) 0.82
Prognosis of patients with recurrent laryngeal carcinoma. Head Neck (2001) 0.82
Hepatitis due to cyproterone acetate. Eur J Cancer (1992) 0.82
Cardiac tamponade as the initial manifestation of primary pericardial mesothelioma. Med Pediatr Oncol (1995) 0.82
Phenotypic characteristics of colo-rectal cancer in I1307K APC germline mutation carriers compared with sporadic cases. Br J Cancer (2001) 0.82
Spontaneous pneumothorax complicating chemotherapy for metastatic seminoma. A case report and a review of the literature. Cancer (1995) 0.81
Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma. J Surg Oncol (1986) 0.81
Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin, and mitomycin C (FAM). Cancer Chemother Pharmacol (1982) 0.81
Second primary lung carcinoma. J Surg Oncol (1980) 0.81
Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol (2001) 0.81
Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity. Am J Reprod Immunol (1998) 0.80
Coronary artery operation in patients after breast cancer therapy. Ann Thorac Surg (1998) 0.80
Genetic analysis of the APC gene regions involved in attenuated APC phenotype in Israeli patients with early onset and familial colorectal cancer. Br J Cancer (2001) 0.80
Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology (1992) 0.80
Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines. Int J Oncol (1999) 0.80
Non-Hodgkin's lymphoma in northern Israel: a study of 481 patients with emphasis on ethnic-related patterns. J Surg Oncol (1989) 0.80
Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake. J Clin Oncol (1995) 0.79
Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature. J Chemother (2005) 0.79
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma. Am J Clin Oncol (1999) 0.79
Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2. Ann Oncol (2004) 0.79
Neutrophil function in cured cancer patients. Cancer (1977) 0.79
[Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas]. Harefuah (1994) 0.79
Aminoglutethimide-induced leukopenia: a case report and review of the literature. Oncology (1984) 0.79
Second-line chemotherapy with mitoxantrone as a single agent in metastatic breast cancer. J Chemother (1993) 0.78
Mechanisms for acquired activated protein C resistance in cancer patients. J Thromb Haemost (2005) 0.78
HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol (2000) 0.78
Radiation therapy for locally advanced breast cancer: prognostic factors and complication rate. Eur J Surg Oncol (1990) 0.78
Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction. J Chemother (2002) 0.78
Antiandrogen withdrawal syndrome with cyproterone acetate. Urology (1998) 0.78
The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of Merkel cell carcinoma. Am J Clin Oncol (1993) 0.78
Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186). Ann Oncol (2002) 0.78
The value of serum copper levels in non-Hodgkin's lymphoma. Cancer (1984) 0.78